FR Doc E6-20689 [Federal Register: December 7, 2006 (Volume 71, Number 235)] [Notices] [Page 70986-70987] From the Federal Register Online via GPO Access [wais.access.gpo.gov] [DOCID:fr07de06-80]

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled Substances; Notice of Registration

By Notice dated July 25, 2006, and published in the Federal Register on July 31, 2006, (71 FR 43211), MGI Pharma, 6611 Tributary Street, Baltimore, Maryland 21224, made application to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of Cocaine (9041),

[[Page 70987]]

a basic class of controlled substance listed in schedule II. The company plans to manufacture a cocaine derivative to be used in domestic and foreign clinical research studies.

No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of MGI Pharma to manufacture the listed basic class of controlled substance is consistent with the public interest at this time. DEA has investigated MGI Pharma to ensure that the company's registration is consistent with the public interest. The investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with State and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic class of controlled substance listed.

Dated: November 28, 2006.

Joseph T. Rannazzisi, 
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. E6-20689 Filed 12-6-06; 8:45 am]

BILLING CODE 4410-09-P

NOTICE: This is an unofficial version. An official version of these publications may be obtained directly from the Government Printing Office (GPO).